Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunotherapy, Adoptive | 54 | 2024 | 1270 | 6.810 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 39 | 2024 | 1378 | 6.070 |
Why?
|
Antigens, CD19 | 32 | 2024 | 380 | 4.700 |
Why?
|
Lymphoma, Follicular | 11 | 2024 | 435 | 4.430 |
Why?
|
Lymphoma, B-Cell | 10 | 2024 | 931 | 3.270 |
Why?
|
Lymphoma, Non-Hodgkin | 9 | 2022 | 1381 | 2.960 |
Why?
|
Biological Products | 22 | 2024 | 860 | 2.950 |
Why?
|
Lymphoma, Mantle-Cell | 10 | 2023 | 233 | 2.550 |
Why?
|
Neurotoxicity Syndromes | 10 | 2023 | 290 | 2.400 |
Why?
|
Receptors, Antigen, T-Cell | 9 | 2023 | 2540 | 1.540 |
Why?
|
Hematopoietic Stem Cell Transplantation | 16 | 2023 | 5442 | 1.290 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 25 | 2023 | 11524 | 1.260 |
Why?
|
Hematology | 2 | 2021 | 221 | 1.190 |
Why?
|
Stem Cell Transplantation | 11 | 2023 | 1620 | 0.970 |
Why?
|
T-Lymphocytes | 17 | 2023 | 10180 | 0.950 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2024 | 180 | 0.850 |
Why?
|
Hematologic Neoplasms | 7 | 2022 | 1832 | 0.820 |
Why?
|
Hepatic Veno-Occlusive Disease | 1 | 2023 | 220 | 0.800 |
Why?
|
Lymphoma | 5 | 2023 | 1877 | 0.780 |
Why?
|
Neoplasm Recurrence, Local | 15 | 2024 | 9239 | 0.720 |
Why?
|
Antibodies, Bispecific | 2 | 2020 | 164 | 0.710 |
Why?
|
Transplantation, Autologous | 16 | 2023 | 2124 | 0.700 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 8 | 2024 | 1596 | 0.680 |
Why?
|
Resorcinols | 1 | 2016 | 38 | 0.570 |
Why?
|
B-Cell Activating Factor | 2 | 2014 | 119 | 0.560 |
Why?
|
Isoxazoles | 1 | 2016 | 216 | 0.510 |
Why?
|
Humans | 121 | 2024 | 744343 | 0.470 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2016 | 434 | 0.460 |
Why?
|
Lymphoproliferative Disorders | 2 | 2023 | 523 | 0.460 |
Why?
|
Vidarabine | 4 | 2024 | 345 | 0.450 |
Why?
|
Hypotension | 1 | 2019 | 884 | 0.440 |
Why?
|
Transplantation, Homologous | 7 | 2023 | 4776 | 0.420 |
Why?
|
Burkitt Lymphoma | 1 | 2014 | 327 | 0.420 |
Why?
|
Transplantation Conditioning | 3 | 2022 | 1598 | 0.420 |
Why?
|
Graft vs Host Disease | 4 | 2021 | 2957 | 0.410 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2014 | 286 | 0.410 |
Why?
|
Leukemia, B-Cell | 1 | 2011 | 86 | 0.400 |
Why?
|
Lymphoma, T-Cell, Peripheral | 2 | 2023 | 134 | 0.390 |
Why?
|
Pyrazoles | 3 | 2019 | 1972 | 0.380 |
Why?
|
Watchful Waiting | 1 | 2015 | 492 | 0.370 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2021 | 5172 | 0.370 |
Why?
|
Tumor Microenvironment | 5 | 2023 | 3586 | 0.350 |
Why?
|
Immunotherapy | 3 | 2023 | 4445 | 0.350 |
Why?
|
Antineoplastic Agents | 5 | 2023 | 13695 | 0.350 |
Why?
|
Cyclophosphamide | 6 | 2024 | 2242 | 0.330 |
Why?
|
Pyrimidines | 3 | 2019 | 2942 | 0.330 |
Why?
|
Hodgkin Disease | 3 | 2022 | 1415 | 0.330 |
Why?
|
Cord Blood Stem Cell Transplantation | 1 | 2011 | 314 | 0.330 |
Why?
|
B-Lymphocytes | 4 | 2019 | 4665 | 0.330 |
Why?
|
Survival Analysis | 9 | 2023 | 10252 | 0.320 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2012 | 693 | 0.320 |
Why?
|
Tumor Escape | 2 | 2021 | 349 | 0.320 |
Why?
|
Adenine | 4 | 2024 | 936 | 0.320 |
Why?
|
Recurrence | 7 | 2021 | 8340 | 0.300 |
Why?
|
Organ Transplantation | 2 | 2023 | 1139 | 0.290 |
Why?
|
Immunologic Factors | 2 | 2019 | 1580 | 0.290 |
Why?
|
Disease Management | 3 | 2020 | 2459 | 0.280 |
Why?
|
Quinazolinones | 2 | 2019 | 221 | 0.270 |
Why?
|
Congresses as Topic | 2 | 2021 | 764 | 0.260 |
Why?
|
Piperidines | 4 | 2024 | 1602 | 0.260 |
Why?
|
Retrospective Studies | 24 | 2024 | 77449 | 0.250 |
Why?
|
Purines | 2 | 2019 | 594 | 0.240 |
Why?
|
Adult | 39 | 2023 | 214055 | 0.240 |
Why?
|
Aged | 37 | 2024 | 163280 | 0.230 |
Why?
|
Adrenal Cortex Hormones | 3 | 2024 | 1855 | 0.230 |
Why?
|
Genomics | 1 | 2019 | 5720 | 0.220 |
Why?
|
Immunoconjugates | 2 | 2020 | 901 | 0.220 |
Why?
|
Polydeoxyribonucleotides | 1 | 2023 | 127 | 0.220 |
Why?
|
Combined Modality Therapy | 5 | 2020 | 8642 | 0.210 |
Why?
|
Sulfonamides | 2 | 2022 | 1938 | 0.210 |
Why?
|
Receptor Aggregation | 2 | 1998 | 80 | 0.210 |
Why?
|
Middle Aged | 39 | 2023 | 213383 | 0.200 |
Why?
|
Cell Count | 2 | 2022 | 1856 | 0.200 |
Why?
|
Tolnaftate | 1 | 2020 | 2 | 0.200 |
Why?
|
Anthracyclines | 1 | 2023 | 288 | 0.200 |
Why?
|
Graft Survival | 1 | 2011 | 3737 | 0.190 |
Why?
|
Antibodies, Monoclonal | 4 | 2023 | 9274 | 0.190 |
Why?
|
Leukoencephalopathies | 1 | 2024 | 238 | 0.190 |
Why?
|
Receptors, Cholinergic | 2 | 1998 | 238 | 0.190 |
Why?
|
Histiocytes | 1 | 2021 | 103 | 0.190 |
Why?
|
Male | 42 | 2023 | 350118 | 0.180 |
Why?
|
Germany | 1 | 2022 | 862 | 0.180 |
Why?
|
Neoplasm Proteins | 3 | 2021 | 3703 | 0.180 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 648 | 0.180 |
Why?
|
Geological Phenomena | 1 | 2019 | 11 | 0.180 |
Why?
|
Cytarabine | 3 | 2020 | 692 | 0.180 |
Why?
|
Agrin | 2 | 1998 | 68 | 0.170 |
Why?
|
Immunity, Innate | 1 | 2011 | 2958 | 0.170 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 692 | 0.170 |
Why?
|
Antigens, CD20 | 1 | 2020 | 199 | 0.170 |
Why?
|
Neoplasm, Residual | 5 | 2023 | 973 | 0.170 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2020 | 113 | 0.170 |
Why?
|
Prognosis | 12 | 2023 | 29063 | 0.170 |
Why?
|
Ambulances | 1 | 2019 | 95 | 0.160 |
Why?
|
Azepines | 1 | 2020 | 336 | 0.160 |
Why?
|
Patient Selection | 3 | 2020 | 4215 | 0.160 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2016 | 3557 | 0.160 |
Why?
|
Female | 43 | 2023 | 380194 | 0.160 |
Why?
|
Oligonucleotides | 1 | 2021 | 572 | 0.160 |
Why?
|
Etoposide | 2 | 2022 | 641 | 0.160 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2022 | 450 | 0.160 |
Why?
|
Antifungal Agents | 1 | 2022 | 730 | 0.150 |
Why?
|
Hospitals | 2 | 2023 | 3952 | 0.150 |
Why?
|
Ferritins | 1 | 2020 | 590 | 0.150 |
Why?
|
Vincristine | 2 | 2022 | 1039 | 0.150 |
Why?
|
Mutation, Missense | 2 | 2016 | 2564 | 0.150 |
Why?
|
BRCA2 Protein | 1 | 2022 | 794 | 0.140 |
Why?
|
Cardiovascular Agents | 1 | 2023 | 850 | 0.140 |
Why?
|
Adoptive Transfer | 1 | 2019 | 844 | 0.140 |
Why?
|
Survival Rate | 6 | 2021 | 12788 | 0.140 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2020 | 324 | 0.140 |
Why?
|
Radioimmunotherapy | 1 | 2016 | 91 | 0.140 |
Why?
|
Leukemia, Hairy Cell | 1 | 2016 | 82 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 193 | 0.140 |
Why?
|
Benzamides | 1 | 2021 | 1379 | 0.130 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 7913 | 0.130 |
Why?
|
Cytoskeletal Proteins | 2 | 1998 | 1364 | 0.130 |
Why?
|
Follow-Up Studies | 8 | 2024 | 39050 | 0.130 |
Why?
|
Pyrazines | 1 | 2021 | 1230 | 0.130 |
Why?
|
Tissue Banks | 1 | 2016 | 184 | 0.130 |
Why?
|
United States | 6 | 2023 | 69872 | 0.130 |
Why?
|
Treatment Outcome | 12 | 2024 | 63114 | 0.130 |
Why?
|
BRCA1 Protein | 1 | 2022 | 1149 | 0.130 |
Why?
|
Salvage Therapy | 3 | 2021 | 1275 | 0.130 |
Why?
|
Prednisone | 2 | 2022 | 1574 | 0.120 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2016 | 337 | 0.120 |
Why?
|
Ifosfamide | 1 | 2014 | 228 | 0.120 |
Why?
|
Consensus | 1 | 2023 | 2959 | 0.120 |
Why?
|
DNA | 2 | 2021 | 7301 | 0.120 |
Why?
|
Prospective Studies | 6 | 2023 | 53288 | 0.110 |
Why?
|
Tumor Burden | 2 | 2020 | 1915 | 0.110 |
Why?
|
Safety | 1 | 2018 | 1186 | 0.110 |
Why?
|
Disease-Free Survival | 6 | 2023 | 6895 | 0.110 |
Why?
|
Myeloablative Agonists | 1 | 2014 | 218 | 0.110 |
Why?
|
Bone Marrow | 1 | 2023 | 2948 | 0.110 |
Why?
|
Doxorubicin | 2 | 2022 | 2234 | 0.110 |
Why?
|
Electroencephalography | 3 | 2023 | 6150 | 0.110 |
Why?
|
Amino Acid Substitution | 1 | 2016 | 1791 | 0.100 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1813 | 0.100 |
Why?
|
Leukocytes, Mononuclear | 3 | 2023 | 1836 | 0.100 |
Why?
|
Lymphocyte Count | 1 | 2014 | 793 | 0.100 |
Why?
|
Risk Factors | 7 | 2023 | 72290 | 0.100 |
Why?
|
Neutropenia | 3 | 2022 | 895 | 0.100 |
Why?
|
Nervous System Diseases | 2 | 2019 | 1622 | 0.100 |
Why?
|
Molecular Targeted Therapy | 2 | 2020 | 2727 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 987 | 0.100 |
Why?
|
Thalidomide | 1 | 2016 | 890 | 0.100 |
Why?
|
Aged, 80 and over | 12 | 2021 | 57776 | 0.090 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2016 | 2455 | 0.090 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 1998 | 1660 | 0.090 |
Why?
|
Membrane Glycoproteins | 2 | 1998 | 3768 | 0.090 |
Why?
|
Heart Diseases | 1 | 2023 | 2788 | 0.090 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 272 | 0.090 |
Why?
|
Monocytes | 1 | 2019 | 2596 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 1434 | 0.090 |
Why?
|
Interleukin-6 | 1 | 2019 | 3200 | 0.090 |
Why?
|
Remission Induction | 3 | 2021 | 2386 | 0.080 |
Why?
|
Terminal Care | 1 | 2021 | 1694 | 0.080 |
Why?
|
Young Adult | 9 | 2021 | 56430 | 0.080 |
Why?
|
Comorbidity | 1 | 2023 | 10388 | 0.080 |
Why?
|
Translocation, Genetic | 1 | 2014 | 1420 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1912 | 0.080 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3778 | 0.080 |
Why?
|
Nuclear Proteins | 2 | 2020 | 5853 | 0.080 |
Why?
|
Proteins | 2 | 2020 | 6103 | 0.080 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2022 | 4479 | 0.080 |
Why?
|
Methotrexate | 1 | 2014 | 1727 | 0.080 |
Why?
|
Leukemia | 1 | 2016 | 1511 | 0.080 |
Why?
|
Neoplasms | 3 | 2022 | 21683 | 0.080 |
Why?
|
Chronic Disease | 2 | 2014 | 9146 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1972 | 0.070 |
Why?
|
HLA Antigens | 2 | 2011 | 1381 | 0.070 |
Why?
|
Epigenesis, Genetic | 1 | 2019 | 3647 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 934 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 2 | 2019 | 5535 | 0.070 |
Why?
|
Steroids | 1 | 2010 | 930 | 0.060 |
Why?
|
Research Design | 2 | 2018 | 5987 | 0.060 |
Why?
|
Immunoglobulin Heavy Chains | 2 | 2019 | 659 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2022 | 4838 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2022 | 5181 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2022 | 4386 | 0.060 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4933 | 0.060 |
Why?
|
Melphalan | 2 | 2022 | 431 | 0.060 |
Why?
|
Positron-Emission Tomography | 3 | 2023 | 6234 | 0.060 |
Why?
|
Incidence | 1 | 2022 | 20947 | 0.060 |
Why?
|
Killer Cells, Natural | 1 | 2011 | 2133 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 142 | 0.050 |
Why?
|
Dystroglycans | 2 | 1998 | 60 | 0.050 |
Why?
|
Interleukin-15 | 1 | 2022 | 184 | 0.050 |
Why?
|
Busulfan | 1 | 2022 | 263 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2016 | 9959 | 0.050 |
Why?
|
Neoplasm Staging | 2 | 2013 | 11031 | 0.050 |
Why?
|
Adolescent | 6 | 2020 | 85781 | 0.050 |
Why?
|
Antigens, CD | 1 | 2011 | 4026 | 0.050 |
Why?
|
Gene Expression | 1 | 2014 | 7799 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2023 | 2916 | 0.050 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2004 | 627 | 0.050 |
Why?
|
North America | 1 | 2023 | 1249 | 0.050 |
Why?
|
Leukapheresis | 1 | 2020 | 131 | 0.050 |
Why?
|
Cell Line, Tumor | 1 | 2016 | 16689 | 0.040 |
Why?
|
Immunoglobulin G | 2 | 2023 | 4560 | 0.040 |
Why?
|
Molecular Biology | 1 | 2023 | 596 | 0.040 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2019 | 38 | 0.040 |
Why?
|
Standard of Care | 1 | 2023 | 564 | 0.040 |
Why?
|
Retreatment | 1 | 2020 | 610 | 0.040 |
Why?
|
Risk | 1 | 2011 | 9687 | 0.040 |
Why?
|
Interferons | 1 | 2022 | 706 | 0.040 |
Why?
|
Water-Electrolyte Balance | 1 | 2020 | 346 | 0.040 |
Why?
|
Tissue Distribution | 2 | 2020 | 2327 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2022 | 618 | 0.040 |
Why?
|
Nepal | 1 | 2019 | 295 | 0.040 |
Why?
|
Central Nervous System Neoplasms | 1 | 2006 | 895 | 0.040 |
Why?
|
Genes, BRCA1 | 1 | 2022 | 781 | 0.040 |
Why?
|
Tuberculosis | 1 | 2010 | 1912 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2020 | 892 | 0.040 |
Why?
|
rac GTP-Binding Proteins | 1 | 1998 | 164 | 0.040 |
Why?
|
src Homology Domains | 1 | 1998 | 364 | 0.040 |
Why?
|
Uterine Neoplasms | 1 | 2006 | 1513 | 0.040 |
Why?
|
Binding, Competitive | 1 | 1998 | 1157 | 0.040 |
Why?
|
Mice | 5 | 2016 | 81183 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6538 | 0.040 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2020 | 430 | 0.030 |
Why?
|
Laminin | 1 | 1998 | 419 | 0.030 |
Why?
|
Litter Size | 1 | 1996 | 54 | 0.030 |
Why?
|
Death | 1 | 2021 | 678 | 0.030 |
Why?
|
Central Nervous System | 1 | 2023 | 1357 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 246 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2019 | 498 | 0.030 |
Why?
|
Signal Transduction | 1 | 1998 | 23403 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2274 | 0.030 |
Why?
|
Age Factors | 3 | 2019 | 18370 | 0.030 |
Why?
|
Small Molecule Libraries | 1 | 2020 | 720 | 0.030 |
Why?
|
Hepatitis, Autoimmune | 1 | 2016 | 141 | 0.030 |
Why?
|
Animals | 7 | 2019 | 168757 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 367 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 222 | 0.030 |
Why?
|
Dexamethasone | 1 | 2021 | 1951 | 0.030 |
Why?
|
Review Literature as Topic | 1 | 2016 | 336 | 0.030 |
Why?
|
Antilymphocyte Serum | 1 | 1995 | 492 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 755 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 380 | 0.030 |
Why?
|
Interleukins | 1 | 2017 | 791 | 0.030 |
Why?
|
Seasons | 1 | 2019 | 1493 | 0.030 |
Why?
|
Muscles | 1 | 1998 | 1614 | 0.030 |
Why?
|
Platelet Transfusion | 1 | 1995 | 314 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2085 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2010 | 5751 | 0.030 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3176 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1878 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2429 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 3913 | 0.020 |
Why?
|
Isoantibodies | 1 | 1995 | 679 | 0.020 |
Why?
|
Heparin | 1 | 1998 | 1637 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3670 | 0.020 |
Why?
|
Mutation | 3 | 2022 | 29786 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5007 | 0.020 |
Why?
|
Disease Progression | 3 | 2013 | 13284 | 0.020 |
Why?
|
Phosphorylation | 2 | 1998 | 8436 | 0.020 |
Why?
|
Heart Failure | 2 | 2023 | 10900 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2023 | 12026 | 0.020 |
Why?
|
Seizures | 1 | 2022 | 2859 | 0.020 |
Why?
|
Stem Cells | 1 | 2022 | 3567 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2948 | 0.020 |
Why?
|
Child | 3 | 2019 | 77709 | 0.020 |
Why?
|
Proteomics | 1 | 2022 | 3638 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9313 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 1998 | 2866 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10943 | 0.020 |
Why?
|
Cohort Studies | 2 | 2022 | 40561 | 0.020 |
Why?
|
Receptors, Estrogen | 1 | 1996 | 2187 | 0.020 |
Why?
|
Logistic Models | 1 | 2022 | 13408 | 0.020 |
Why?
|
Societies, Medical | 1 | 2019 | 3743 | 0.020 |
Why?
|
Genotype | 1 | 2022 | 12951 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3022 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 1995 | 2765 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2504 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1799 | 0.020 |
Why?
|
Swine | 1 | 1996 | 5917 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 1998 | 4554 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2488 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7785 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10397 | 0.020 |
Why?
|
Thiotepa | 1 | 2004 | 66 | 0.020 |
Why?
|
Blood Platelets | 1 | 1995 | 2508 | 0.020 |
Why?
|
Carrier Proteins | 1 | 1998 | 5021 | 0.020 |
Why?
|
Cell Line | 1 | 1998 | 15997 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 3597 | 0.010 |
Why?
|
Internet | 1 | 2016 | 3064 | 0.010 |
Why?
|
Tomography, Emission-Computed | 1 | 2006 | 1144 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5319 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2006 | 1850 | 0.010 |
Why?
|
Carboplatin | 1 | 2004 | 801 | 0.010 |
Why?
|
Membrane Proteins | 1 | 1998 | 7880 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10638 | 0.010 |
Why?
|
Liver | 1 | 2016 | 7474 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2016 | 9438 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 40075 | 0.010 |
Why?
|
Infant | 2 | 2019 | 35136 | 0.010 |
Why?
|
Child, Preschool | 2 | 2019 | 41006 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2022 | 35421 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-crk | 1 | 1998 | 13 | 0.010 |
Why?
|
Son of Sevenless Proteins | 1 | 1998 | 27 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16365 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 29144 | 0.010 |
Why?
|
Paclitaxel | 1 | 2004 | 1708 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2004 | 20822 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15540 | 0.010 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1996 | 768 | 0.010 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 1998 | 581 | 0.010 |
Why?
|
Histocompatibility | 1 | 1995 | 330 | 0.010 |
Why?
|
Drug Interactions | 1 | 1998 | 1460 | 0.010 |
Why?
|
HeLa Cells | 1 | 1998 | 3128 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 14722 | 0.010 |
Why?
|
Blotting, Western | 1 | 1998 | 5179 | 0.010 |
Why?
|
Genetic Linkage | 1 | 1996 | 2421 | 0.010 |
Why?
|
Cell Separation | 1 | 1995 | 1751 | 0.010 |
Why?
|
Genetic Markers | 1 | 1996 | 2634 | 0.010 |
Why?
|
Leukocytes | 1 | 1995 | 2043 | 0.000 |
Why?
|